



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 731 165 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73

(51) Int Cl.7: **C12N 15/10**, C07K 14/155,
G01N 33/569

(48) Corrigendum issued on:
10.08.2005 Bulletin 2005/32

(45) Date of publication and mention
of the grant of the patent:
15.06.2005 Bulletin 2005/24

(21) Application number: **96200578.1**

(22) Date of filing: **04.03.1996**

(54) **Human T-cell line infected with HIV-2 which secretes functionally intact HIV-2 GP160**

Mit HIV-2 infizierte menschliche T-Zelllinie die funktionell intaktes HIV-2 gp160 sekretiert

Lignée de lymphocytes-T humaine, infectée par le HIV-2 sécrétant une HIV-2 gp160 fonctionnellement intacte

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **07.03.1995 US 402481**

(43) Date of publication of application:
11.09.1996 Bulletin 1996/37

(73) Proprietor: **bioMérieux, Inc.**
Durham, NC 27712 (US)

(72) Inventors:
• **Sarngadharan, Mangalasseril Gopalan**
McLean, VA 22101 (US)

• **Kalyanaraman, Vaniambadi Srinivasan**
Germantown, MD 20874 (US)
• **Larue Kalisz, Irene**
Frederick, MD 21704 (US)

(74) Representative: **Prins, Hendrik Willem et al**
Arnold & Siedsma,
Advocaten en Octrooigemachtigden,
Sweelinckplein 1
2517 GK Den Haag (NL)

(56) References cited:
WO-A-89/06276 **US-A- 5 116 740**
US-A- 5 122 468

EP 0 731 165 B8

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).